Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Immunology of Diffuse Large B-cell Lymphomas and Other Aggressive B-cell...
share announcement

Immunology of Diffuse Large B-cell Lymphomas and Other Aggressive B-cell Lymphomas

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 13737

Special Issue Editor

Prof. Dr. Daan Dierickx

E-Mail Website
Guest Editor
1. Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium
2. Department of Oncology, University Hospitals Leuven, 3000 Leuven, Belgium
Interests: lymphoma; B-cell; immunology; treatment

Special Issue Information

Dear Colleagues,

Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma, representing a heterogeneous disease with variable prognosis. The most common subtype, accounting for about 80-85% of all cases, is designated as DLBCL, NOS (not otherwise specified). Despite improved knowledge on pathogenesis of DLBCL leading to several phase III trials with targeted therapy, rituximab and CHOP remains the standard of care for first line therapy. In addition, several rare DLBCL subtypes (for example primary central nervous system lymphoma, primary mediastinal B-cell lymphoma,…) require more specific treatment. During the last years, new immunotherapeutic strategies have revolutionized the therapeutic landscape of DLBCL. These new therapeutic options include enhanced monoclonal antibodies, immunoconjugates, bispecific T-cell engagers (BiTe) and chimeric antigen receptor T-cells (CART).  Burkitt lymphoma and high grade B-cell lymphoma (also known as double hit lymphoma if MYC, BCL2 and/or BCL6 rearrangements) are other subtypes of aggressive B-cell lymphomas, with distinct underlying pathogenic mechanisms. This Special Issue will highlight immunological aspects of DLBCL or other aggressive B-cell lymphoma, both from diagnostic or therapeutic point of view.

Prof. Dr. Daan Dierickx
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diffuse large B-cell lymphoma 
  • Burkitt lymphoma 
  • high grade B-cell lymphoma 
  • pathogenesis 
  • immunotherapy 
  • monoclonal antibody 
  • bispecific T-cell engagers 
  • chimeric antigen receptor T-cells

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

20 pages, 1129 KiB  
Review
The Immunology of DLBCL
by Taishi Takahara, Shigeo Nakamura, Toyonori Tsuzuki and Akira Satou
Cancers 2023, 15(3), 835; https://doi.org/10.3390/cancers15030835 - 29 Jan 2023
Cited by 36 | Viewed by 7166
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and is the most common type of malignant lymphoid neoplasm. While some DLBCLs exhibit strong cell-autonomous survival and proliferation activity, others depend on interactions with non-malignant cells for their survival and proliferation. Recent next-generation [...] Read more.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and is the most common type of malignant lymphoid neoplasm. While some DLBCLs exhibit strong cell-autonomous survival and proliferation activity, others depend on interactions with non-malignant cells for their survival and proliferation. Recent next-generation sequencing studies have linked these interactions with the molecular classification of DLBCL. For example, germinal center B-cell-like DLBCL tends to show strong associations with follicular T cells and epigenetic regulation of immune recognition molecules, whereas activated B-cell-like DLBCL shows frequent genetic aberrations affecting the class I major histocompatibility complex. Single-cell technologies have also provided detailed information about cell–cell interactions and the cell composition of the microenvironment of DLBCL. Aging-related immunological deterioration, i.e., immunosenescence, also plays an important role in DLBCL pathogenesis, especially in Epstein-Barr virus-positive DLBCL. Moreover, DLBCL in “immune-privileged sites”—where multiple immune-modulating mechanisms exist—shows unique biological features, including frequent down-regulation of immune recognition molecules and an immune-tolerogenic tumor microenvironment. These advances in understanding the immunology of DLBCL may contribute to the development of novel therapies targeting immune systems. Full article
(This article belongs to the Special Issue Immunology of Diffuse Large B-cell Lymphomas and Other Aggressive B-cell Lymphomas)
►▼ Show Figures

Figure 1

19 pages, 1373 KiB  
Review
In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies
by Matylda Kubacz, Aleksandra Kusowska, Magdalena Winiarska and Małgorzata Bobrowicz
Cancers 2023, 15(1), 235; https://doi.org/10.3390/cancers15010235 - 30 Dec 2022
Cited by 4 | Viewed by 5997
Abstract
Despite the high incidence of diffuse large B-cell lymphoma (DLBCL), its management constitutes an ongoing challenge. The most common DLBCL variants include activated B-cell (ABC) and germinal center B-cell-like (GCB) subtypes including DLBCL with MYC and BCL2/BCL6 rearrangements which vary among each other [...] Read more.
Despite the high incidence of diffuse large B-cell lymphoma (DLBCL), its management constitutes an ongoing challenge. The most common DLBCL variants include activated B-cell (ABC) and germinal center B-cell-like (GCB) subtypes including DLBCL with MYC and BCL2/BCL6 rearrangements which vary among each other with sensitivity to standard rituximab (RTX)-based chemoimmunotherapy regimens and lead to distinct clinical outcomes. However, as first line therapies lead to resistance/relapse (r/r) in about half of treated patients, there is an unmet clinical need to identify novel therapeutic strategies tailored for these patients. In particular, immunotherapy constitutes an attractive option largely explored in preclinical and clinical studies. Patient-derived cell lines that model primary tumor are indispensable tools that facilitate preclinical research. The current review provides an overview of available DLBCL cell line models and their utility in designing novel immunotherapeutic strategies. Full article
(This article belongs to the Special Issue Immunology of Diffuse Large B-cell Lymphomas and Other Aggressive B-cell Lymphomas)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop